Prevalence and genotype distribution of human papillomavirus infections in women attending hospitals in Chaozhou of Guangdong Province

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 4, 2012, Pages 1519-1524

  Chen, Qiang ^a,b   Luo, Zhao Yun ^b   Lin, Min ^b   Lin, Qi Li ^c   Chen, Chan Yu ^d   Yang, Chun ^d   Xie, Long Xu ^e   Li, Hui ^f   Zheng, Jia Kun ^b   Yang, Li Ye ^b   Ju, Gui Zhi ^a  

^a JILIN UNIVERSITY   (China)

^b Laboratory Medicine Center   (China)

^c Chaozhou Central Hospital Affiliated to Southern Medical University   (China)

^d Chaozhou People's Hospital   (China)

^e Hybribio Limited Corporation   (China)

^f Chaozhou Gynecological and Pediatric Hospital   (China)

Author keywords

China; Guangdong; Human papillomavirus; Outpatients; Prevalence

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHINA; CONFIDENCE INTERVAL; FEMALE; GENETICS; GENOTYPE; HUMAN; MIDDLE AGED; MIXED INFECTION; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PREVALENCE; RISK; STATISTICAL MODEL; UTERINE CERVIX; VAGINA SMEAR; VIROLOGY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CERVIX UTERI; CHINA; COINFECTION; CONFIDENCE INTERVALS; FEMALE; GENOTYPE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; ODDS RATIO; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; VAGINAL SMEARS; YOUNG ADULT;

EID: 84873031632     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.4.1519     Document Type: Article

References (29)

1. Bao YP, Li N, Smith JS, et al (2008). Human papillomavirus type distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer, 18, 71-9.
2. Bosch FX, Lorincz A, Muñoz N, et al (2002). The causal relation between human papillomavirus and cervical cancer. J Clin Pathol, 55, 244-65.
3. Bruni L, Diaz M, Castellsagué X, et al (2010). Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis, 202, 1789-99.
4. Bouvard V, Baan R, Straif K, et al (2009). A review of human carcinogens-Part B: biological agents. Lancet Oncol, 10, 321-2.
5. Chen HC, Schiffman M, Lin CY, et al (2011). Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst, 103, 1387-96.
6. Chen Q, Xie LX, Qing ZR, et al (2012). Epidemiologic characterization of human papillomavirus infection in rural chaozhou, eastern guangdong province of china. PLoS One, 7, e32149.
7. Clifford GM, Gallus S, Herrero R, et al (2005). Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet, 366, 991-8.
8. de Sanjosé S, Diaz M, Castellsagué X, et al (2007). Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis, 7, 453-9.
9. Dunne EF, Unger ER, Sternberg M, et al (2007). Prevalence of HPV infection among females in the United States. JAMA, 297, 813-9.
10. Inoue M, Sakaguchi J, Sasagawa T, et al (2006). The evaluation of human papillomavirus DNA testing in primary screening for cervical lesions in a large Japanese population. Int J Gynecol Cancer, 16, 1007-13.
11. Harper DM, Franco EL, Wheeler C, et al (2004). Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet, 364, 1757-65.
12. Herrero R (2009). Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J Infect Dis, 199, 919-22.
13. Hildesheim A, Wang SS (2002). Host and viral genetics and risk of cervical cancer: a review. Virus Res, 89, 229-40.
14. Lin H, Ma YY, Moh JS, et al (2006). High prevalence of genital human papillomavirus type 52 and 58 infection in women attending gynecologic practitioners in South Taiwan. Gynecol Oncol, 101, 40-5.
15. Lin M, Yang LY, Li LJ, et al (2008). Genital human papillomavirus screening by gene chip in Chinese women of Guangdong province. Aust N Z J Obstet Gynaecol, 48, 189-94.
16. Liu SS, Chan KY, Leung RC, et al (2011). Prevalence and risk factors of Human Papillomavirus (HPV) infection in southern Chinese women - a population-based study. PLoS One, 6, e19244.
17. Klintschar M, Neuhuber F (2000). Evaluation of an alkaline lysis method for the extraction of DNA from whole blood and forensic stains for STR analysis. J Forensic Sci, 45, 669-73.
18. Middleton K, Peh W, Southern S, et al (2003). Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J Virol, 77, 10186-201.
19. Muñoz N, Bosch FX, de Sanjosé S, et al (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med, 348, 518-27.
20. Solomon D, Davey D, Kurman R, et al (2002). The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA, 287, 2114-9.
21. Sun ZR, Ji YH, Zhou WQ, et al (2010). Characteristics of HPV prevalence among women in Liaoning province, China. Int J Gynaecol Obstet, 109, 105-9.
22. Trottier H, Burchell AN (2009). Epidemiology of mucosal human papillomavirus infection and associated diseases. Public Health Genomics, 12, 291-307.
23. Villa LL, Costa RL, Petta CA, et al (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol, 6, 271-8.
24. Wu D, Cai L, Huang M, et al (2010). Prevalence of genital human papillomavirus infection and genotypes among women from Fujian province, PR China. Eur J Obstet Gynecol Reprod Biol, 151, 86-90.
25. Xue Y, Zhang W, Chen M, et al (2009). "U" shape of age-specific prevalence of high-risk human papillomavirus infection in women attending hospitals in Shanghai, China. Eur J Obstet Gynecol Reprod Biol, 145, 214-8.
26. Yang L, Parkin DM, Li L, et al (2003). Time trends in cancer mortality in China: 1987-1999. Int J Cancer, 106, 771-83.
27. Ye J, Cheng X, Chen X, et al (2010). Prevalence and risk profile of cervical Human papillomavirus infection in Zhejiang Province, southeast China: a population-based study. Virol J, 7, 66.
28. Yip YC, Ngai KL, Vong HT, et al (2010). Prevalence and genotype distribution of cervical human papillomavirus infection in Macao. J Med Virol, 82, 1724-9.
29. Yoshikawa H (2009). Progress and challenges on HPV vaccination. Uirusu, 59, 243-8.